Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025 [Yahoo! Finance]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Yahoo! Finance
BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the company will have three poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025, including the first clinical data on the novel CoREST inhibitor TNG260 in non-small cell lung cancer. SITC will be held November 5-9, 2025 in National Harbor, Maryland. TNG260 is a first-in-class, highly selective CoREST complex inhibitor currently being evaluated with pembrolizumab in the dose expansion phase of the TNG260 Phase 1/2 trial. The trial is currently enrolling patients with STK11-mutant/RAS wild type lung cancer, approximately ~10% of lung adenocarcinoma. Abstracts accepted for poster presentation Title: A Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TNG260 in combination wit
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics (NASDAQ:TNGX) was given a new $15.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy [Seeking Alpha]Seeking Alpha
- Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at B. Riley from $8.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
TNGX
Earnings
- 11/4/25 - Beat
TNGX
Sec Filings
- 11/21/25 - Form SCHEDULE
- 11/21/25 - Form 8-K
- 11/21/25 - Form S-3ASR
- TNGX's page on the SEC website